Valuation: Alumis Inc.

Market Cap 3.22B 2.78B 2.62B 2.38B 4.47B 309B 4.54B 30.7B 12.03B 154B 12.09B 11.83B 514B P/E 2026 *
-7.65x
P/E 2027 * -8.89x
Enterprise Value 2.5B 2.16B 2.04B 1.85B 3.48B 240B 3.53B 23.87B 9.36B 120B 9.4B 9.2B 400B EV / Sales 2026 *
391x
EV / Sales 2027 * 111x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-2.43%
1 week-1.93%
Current month-11.93%
1 month-13.19%
3 months+17.64%
6 months-9.56%
Current year+154.92%
1 week 23.13
Extreme 23.13
25.86
1 month 23.13
Extreme 23.13
30.11
Current year 7.85
Extreme 7.85
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 63 01/05/2021
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

Chief Technology Officer

-2,447 0.0020%
03/08/26 Sell

Executive/Senior Manager

-2,692 0.0022%
03/08/26 Sell

General Counsel

-1,364 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-2.43%-1.93%+412.99% - 3.22B
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.57%+14.98%+56.53%+91.84% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
+0.95%+4.27%+40.15%-14.87% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average -0.35%+3.08%+92.57%+197.66% 28.37B
Weighted average by Cap. +0.02%+5.60%+61.20%+164.30%

Financials

2026 *2027 *
Net sales 6.4M 5.53M 5.2M 4.73M 8.89M 613M 9.02M 61.02M 23.91M 307M 24.03M 23.51M 1.02B 24.33M 21.02M 19.78M 17.97M 33.8M 2.33B 34.3M 232M 90.91M 1.17B 91.37M 89.38M 3.88B
Net income -426M -368M -346M -315M -592M -40.85B -601M -4.06B -1.59B -20.43B -1.6B -1.57B -68.05B -409M -353M -332M -302M -568M -39.15B -576M -3.9B -1.53B -19.58B -1.53B -1.5B -65.23B
Net Debt -716M -618M -582M -529M -995M -68.6B -1.01B -6.83B -2.67B -34.31B -2.69B -2.63B -114B -514M -444M -418M -380M -714M -49.24B -724M -4.9B -1.92B -24.63B -1.93B -1.89B -82.03B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
18/08/26 $24.88 -2.43% 661,654
17/08/26 $25.50 +0.75% 843,995
14/08/26 $25.31 +3.69% 1,217,495
13/08/26 $24.41 -4.46% 832,442
12/08/26 $25.55 +0.71% 991,904
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
24.88USD
Average target price
40.33USD
Spread / Average Target
+62.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock